Engineered immune cells take on stubborn anemia
Disease control
Not yet recruiting
This early-stage trial tests a new treatment called CD19/BCMA CAR-T cell therapy for people with a severe type of autoimmune anemia that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to attack the faulty immune cells cau…
Phase: PHASE1, PHASE2 • Sponsor: Yihao Wang • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC